Neuroendocrine carcinoma metastatic
Not recruitingStudy of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment
Study of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment
- Disease:Neuroendocrine carcinoma metastatic
- Substances:CarboplatinDurvalumab+1
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica





